<DOC>
	<DOC>NCT02519413</DOC>
	<brief_summary>The primary objective of the study is to retrospectively investigate changes in lymphocyte counts and lymphocyte subtypes, with a focus on CD4+ and CD8+ T cells, in participants on Tecfidera therapy for at least 6 months. The secondary objective is to investigate changes in lymphocyte subtypes other than CD4+ and CD8+ T cells.</brief_summary>
	<brief_title>Tecfidera Lymphocyte Chart Review</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Initiated Tecfidera treatment for the first time on or after 27 March 2013 and received at least 6 months of continuous treatment with Tecfidera Clinical diagnosis of a relapsing form of MS A baseline measurement for ALC and absolute CD4+ or CD8+ count within 6 months prior to Tecfidera initiation At least 1 measurement for ALC and absolute CD4+ or CD8+ count while on Tecfidera therapy for at least 6 months Key Clinical diagnosis of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) prior to Tecfidera initiation Participation in DEFINE 109MS301 (NCT00420212) or CONFIRM 109MS302 (NCT00451451) NOTE: Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>lymphocyte</keyword>
	<keyword>serious infections</keyword>
	<keyword>opportunistic infections</keyword>
	<keyword>Relapsing Forms</keyword>
</DOC>